Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06550024 · ClinicalTrials.gov registry record · NA

SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization

A NA study of Osteoarthritis and Arthritis, sponsored by CrannMed.

Active
Registry status
NA
Development phase
89
Enrollment target
8
Study locations

NCT06550024 is a NA study of Osteoarthritis and Arthritis that is active but no longer recruiting, run by CrannMed. The registered enrollment target is 89 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (89% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06550024, a NA study of Osteoarthritis and Arthritis, is active but no longer recruiting, sponsored by CrannMed.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
89 participants
Enrollment target
8
Study locations

Study Summary

An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).

Interventions

  • DRUG Corticosteroid Injection
  • DEVICE SakuraBead Resorbable Microspheres

Study Locations (8)

Other

  • Bokhua Memorial Cardiovascular Center - Tbilisi
  • Royal Berkshire NHS Foundation Trust - Reading

Alabama

  • University of Alabama Medicine - Birmingham

California

  • Harbor UCLA Medical Center - Torrance

Florida

  • Advanced Vascular Institute - Panama City

North Carolina

  • IR Centers - Raleigh

Virginia

  • IR Centers - Leesburg

Uzbekistan

  • Nano Medical Clinic - Tashkent

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2024-11-28
Est. Completion 2028-10
Phase NA

Sponsor

CrannMed

1 total trials

What the Registry Record Tells You About NCT06550024

The ClinicalTrials.gov registry entry for NCT06550024 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (89% lower). The listed sponsor is CrannMed, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Corticosteroid Injection is the first listed.

NCT06550024 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Other, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT06550024 about?

NCT06550024 is a clinical study titled "SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization". An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).

What is the current status of trial NCT06550024?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 89 participants. The study started on 2024-11-28. Estimated completion is 2028-10.

What conditions does trial NCT06550024 study?

This clinical trial studies the following conditions: Osteoarthritis, Arthritis, Osteo Arthritis Knee, Musculoskeletal Diseases, Rheumatic Diseases.

What interventions are being tested in trial NCT06550024?

The interventions under investigation include: Corticosteroid Injection (DRUG), SakuraBead Resorbable Microspheres (DEVICE).

Who is sponsoring clinical trial NCT06550024?

This trial is sponsored by CrannMed, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06550024 being conducted?

This trial has 8 study locations across Alabama, California, Florida, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.